X4 Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $217.0M | $55.7M | $99.2M | $121.7M | $81.8M | $78.7M | $126.2M | $8.1M |
| Accounts Receivable | $573.0K | $1.1M | $0 | — | — | — | — | — |
| Inventory | — | $2.8M | $0 | — | — | — | — | — |
| Total Current Assets | $261.6M | $112.2M | $122.1M | $128.7M | $87.9M | $83.3M | $129.3M | $9.3M |
| Property, Plant & Equipment | $182.0K | $776.0K | $745.0K | $1.1M | $1.5M | $1.2M | $403.0K | $241.0K |
| Goodwill | $17.4M | $17.4M | $17.4M | $17.4M | $17.4M | $27.1M | $27.1M | $0 |
| Intangible Assets (Excl. Goodwill) | $9.3M | $10.0M | $0 | — | — | — | — | — |
| Total Assets | $290.5M | $146.4M | $147.3M | $155.6M | $117.2M | $122.9M | $160.7M | $9.9M |
| Liabilities | ||||||||
| Accounts Payable | $5.7M | $8.6M | $8.9M | $7.8M | $4.3M | $3.1M | $2.1M | $3.0M |
| Total Current Liabilities | $25.8M | $32.9M | $22.9M | $22.3M | $14.0M | $11.9M | $9.4M | $7.9M |
| Long-Term Debt | $75.0M | $75.0M | $54.6M | $32.3M | $33.1M | $33.2M | $20.0M | $8.3M |
| Total Liabilities | $104.2M | $124.3M | $96.2M | $81.5M | $52.8M | $50.1M | $31.5M | $21.6M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-594.6M | $-515.4M | $-477.9M | $-376.7M | $-282.9M | $-194.2M | $-132.0M | $-79.2M |
| Total Stockholders' Equity | $186.3M | $22.1M | $51.1M | $74.1M | $64.4M | $72.8M | $129.2M | $-77.1M |